No Data
Anhui Anke Biotechnology (300009.SZ): The product "Ansu Meng" pre-filled injection is currently a completely new second-generation growth hormone aqueous solution that is the only one without preservatives, making it safer to use.
On March 18, GELONGHUI reported that Anhui Anke Biotechnology (300009.SZ) stated on the investor interaction platform that the company's product "Ansu Meng" pre-filled injection is currently a brand new second-generation, the only growth hormone aqueous solution without preservatives, making it safer to use. The company focuses on customer feedback and has established a comprehensive customer service system that can promptly solve the problems faced by patients and medical institutions during the use of its products, enhancing the patient experience.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Is Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Stock's Recent Performance A Reflection Of Its Financial Health?
Weisheng Pharmaceutical-B (02561) plans to globally issue 9.9 million shares, bringing in cornerstone investors such as Anhui Anke Biotechnology and Yuanfeng.
Weisheng Pharmaceuticals-B (02561) will conduct its initial public offering from March 13 to March 18, 2025, planning a Global offering of 990...
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Director Zhao Hui of Anhui Anke Biotechnology (300009.SZ) has completed a Shareholding reduction, totaling 0.2 million shares.
Anhui Anke Biotechnology (300009.SZ) announced that the shareholding reduction plan of Director Zhao Hui has been completed, as of 2025...
Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE:300009) Looks Inexpensive But Perhaps Not Attractive Enough
